source
- Sionna’s cystic fibrosis candidate misses primary endpoint in Phase 2 trial, shares plungeSionna Therapeutics announced that its experimental cystic fibrosis drug SION-719 failed to meet the primary endpoint in a Phase 2 trial that added the drug to Vertex Pharmaceuticals' Trikafta. Th…
- FDA rejects ITM-11 radiopharmaceutical over manufacturing flaws, halting rival to Novartis therapyThe U.S. Food and Drug Administration issued a rejection letter for ITM-11, a radiopharmaceutical therapy developed by ITM Isotope Technologies Munich, citing manufacturing problems that prevent ap…